- Home
- PMEC vs KLRS Comparison
PMEC vs KLRS Comparison
Compare PMEC & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- KLRS
- Stock Information
- Founded
- PMEC 1984
- KLRS 2019
- Country
- PMEC Singapore
- KLRS United States
- Employees
- PMEC N/A
- KLRS N/A
- Industry
- PMEC
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMEC
- KLRS Health Care
- Exchange
- PMEC Nasdaq
- KLRS Nasdaq
- Market Cap
- PMEC 56.9M
- KLRS 46.0M
- IPO Year
- PMEC 2023
- KLRS N/A
- Fundamental
- Price
- PMEC $1.87
- KLRS $3.89
- Analyst Decision
- PMEC
- KLRS Strong Buy
- Analyst Count
- PMEC 0
- KLRS 2
- Target Price
- PMEC N/A
- KLRS $23.00
- AVG Volume (30 Days)
- PMEC 244.2K
- KLRS 689.3K
- Earning Date
- PMEC 01-01-0001
- KLRS 08-13-2025
- Dividend Yield
- PMEC N/A
- KLRS N/A
- EPS Growth
- PMEC N/A
- KLRS N/A
- EPS
- PMEC N/A
- KLRS N/A
- Revenue
- PMEC $74,349,000.00
- KLRS N/A
- Revenue This Year
- PMEC N/A
- KLRS N/A
- Revenue Next Year
- PMEC N/A
- KLRS N/A
- P/E Ratio
- PMEC N/A
- KLRS N/A
- Revenue Growth
- PMEC 2.52
- KLRS N/A
- 52 Week Low
- PMEC $0.54
- KLRS $2.14
- 52 Week High
- PMEC $1.89
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- PMEC 62.47
- KLRS 57.01
- Support Level
- PMEC $1.76
- KLRS $2.37
- Resistance Level
- PMEC $1.88
- KLRS $4.90
- Average True Range (ATR)
- PMEC 0.15
- KLRS 0.67
- MACD
- PMEC 0.02
- KLRS 0.04
- Stochastic Oscillator
- PMEC 96.92
- KLRS 29.20
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.